Kiora Pharmaceuticals, Inc.

KPRX · Nasdaq · United States

Share price · KPRX

$0.82-1.77 (-68.15%) 3M

close as of 2026-11-18 · 24h delayed · vol 120K (2.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when KPRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026-11.3%

    Nothing announced by KPRX that day or the session before.

  2. 16 Nov 2026-20.2%
  3. 30 Oct 2026-11.4%
  4. 29 Oct 2026-25.4%
  5. 25 Aug 2026-5.8%

    Nothing announced by KPRX that day or the session before.

  6. 9 Apr 2026-13.3%

    Nothing announced by KPRX that day or the session before.

  7. 8 Apr 2026+32.4%
  8. 7 Apr 2026+6.9%
  9. 9 Mar 2026+8.1%

    Nothing announced by KPRX that day or the session before.

  10. 29 Jan 2026+7.5%

    Nothing announced by KPRX that day or the session before.

Share of unusual movement by asset

For each asset, the share of KPRX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
KIO-301
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—38%
Sessions with no dated event—62%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
Retinal ion channels (light-gated photoswitch)Small molecule
Retinitis Pigmentosa

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
August 2027 (1)
KIO-301Phase 2Retinitis Pigmentosa
Est. primary completion 2027-08 · NCT06628947 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$1.0M$1.9M$5.6M+ $11M short-term inv.$1.8M-$0.6M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$2.1M$7.1M+ $9.8M short-term inv.$2.1M-$1.9M operating cash flowreport ↗
2026-Q1—$2.1M$11M+ $2.9M short-term inv.$2.4M-$3.2M operating cash flowreport ↗
2025-Q3$0$2.7M$5.5M+ $14M short-term inv.—-$1.3M operating cash flowreport ↗
2025-Q2$0$2.6M$1.0M+ $20M short-term inv.$2.1M-$3.8M operating cash flowreport ↗
2025-Q1$0$2.5M$3.8M+ $20M short-term inv.$2.2M-$2.7M operating cash flowreport ↗
2024-Q3$0$1.3M$5.6M+ $23M short-term inv.$3.4M$0.9M operating cash flowreport ↗
2024-Q2<$0.1M$0.9M$6.6M+ $21M short-term inv.$2.2M-$3.7M operating cash flowreport ↗
2024-Q1$16M$1.5M$31M—$14M operating cash flowreport ↗
2023-Q3$0$1.1M$5.4M$5.8M-$2.5M operating cash flowreport ↗
2023-Q2$0$1.4M$8.0M$2.6M-$1.4M operating cash flowreport ↗
2023-Q1$0$0.4M$3.4M$1.9M-$3.1M operating cash flowreport ↗
2022-Q3—$1.3M$4.8M$5.1M-$3.0M operating cash flowreport ↗
2022-Q2—$0.6M$2.5M$2.4M-$2.5M operating cash flowreport ↗
2022-Q1—$0.7M$5.1M$3.6M-$2.8M operating cash flowreport ↗
2021-Q3—$1.6M$11M$3.0Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$11M$8.7M+ $8.4M short-term inv.$2.7M-$10.0M operating cash flowreport ↗

For fiscal 2025, Kiora Pharmaceuticals reported revenue of $0M, down 100.0% YoY from $16.02M in 2024, which had reflected a $16.0M upfront collaboration payment from Laboratoires Théa. R&D expense was $10.78M, up 37.5% YoY. The company ended 2025 with $17.1M in cash, cash equivalents, and short-term investments (including $8.7M of cash and equivalents) and posted a net loss of $10.84M versus net income of $3.6M in 2024; net cash used in operating activities was $2.2M in Q4 and $10.0M for the full year.

Management guided that existing cash, cash equivalents, and short-term investments should fund operations into late 2027, beyond anticipated topline data readouts for the ABACUS-2 and KLARITY trials. The company advanced KIO-301 to patient dosing in the Phase 2 ABACUS-2 trial for advanced retinitis pigmentosa, with an initial data readout anticipated in Q3 2027, and entered an option agreement with Senju Pharmaceutical covering key Asian markets for a potential deal value of up to $110M plus royalties. KIO-104 was advanced to patient dosing in the Phase 2 KLARITY trial for macular edema due to retinal inflammation, and KIO-300 demonstrated preclinical ex vivo proof of concept as an ion-channel modulator in epilepsy.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$16M$7.8M$3.8M+ $23M short-term inv.—$8.6M operating cash flowreport ↗
2023-FY$0$4.0M$2.5M+ $0 short-term inv.$3.1M-$9.6M operating cash flowreport ↗
2022-FY—$3.5M$6.0M$3.4M-$10M operating cash flowreport ↗
2021-FY—$5.3M$7.9M$4.1M-$11M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-17Lane Keith J. · EVP, Clinical and RegulatoryAward / grant (derivative)55,000——Form 4
2026-07-01Strem Brian M. · director, President and CEOTax withholding1,869$2.66$5KForm 4
2026-07-01Tosca Melissa · CFOTax withholding911$2.66$2KForm 4
2026-06-10TYLE PRAVEEN · directorAward / grant (derivative)40,000——Form 4
2026-06-10Walters-Hoffert Lisa · directorAward / grant (derivative)25,000——Form 4
2026-06-10Hollander David · directorAward / grant (derivative)25,000——Form 4
2026-06-10Parsons Erin · directorAward / grant (derivative)25,000——Form 4
2026-06-10Shapiro Aron · directorAward / grant (derivative)25,000——Form 4